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BACKGROUND: Positron emission tomography (PET) using 18F-sodium 
fluoride (18F-fluoride) to detect microcalcification may provide insight into 
disease activity in coronary atherosclerosis. This study aimed to investigate 
the relationship between 18F-fluoride uptake and progression of coronary 
calcification in patients with clinically stable coronary artery disease.
METHODS: Patients with established multivessel coronary atherosclerosis 
underwent 18F-fluoride PET-computed tomography angiography and computed 
tomography calcium scoring, with repeat computed tomography angiography 
and calcium scoring at one year. Coronary PET uptake was analyzed 
qualitatively and semiquantitatively in diseased vessels by measuring maximum 
tissue-to-background ratio. Coronary calcification was quantified by measuring 
calcium score, mass, and volume.
RESULTS: In a total of 183 participants (median age 66 years, 80% male), 
116 (63%) patients had increased 18F-fluoride uptake in at least one vessel. 
Individuals with increased 18F-fluoride uptake demonstrated more rapid 
progression of calcification compared with those without uptake (change 
in calcium score, 97 [39–166] versus 35 [7–93] AU; P<0.0001). Indeed, the 
calcium score only increased in coronary segments with 18F-fluoride uptake 
(from 95 [30–209] to 148 [61–289] AU; P<0.001) and remained unchanged 
in segments without 18F-fluoride uptake (from 46 [16–113] to 49 [20–115] 
AU; P=0.329). Baseline coronary 18F-fluoride maximum tissue-to-background 
ratio correlated with 1-year change in calcium score, calcium volume, and 
calcium mass (Spearman ρ=0.37, 0.38, and 0.46, respectively; P<0.0001 for 
all). At the segmental level, baseline 18F-fluoride activity was an independent 
predictor of calcium score at 12 months (P<0.001). However, at the patient 
level, this was not independent of age, sex, and baseline calcium score 
(P=0.50).
CONCLUSIONS: Coronary 18F-fluoride uptake identifies both patients and 
individual coronary segments with more rapid progression of coronary 
calcification, providing important insights into disease activity within the 
coronary circulation. At the individual patient level, total calcium score 
remains an important marker of disease burden and progression.
REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: 
NCT02110303.
© 2020 The Authors. Circulation: 
Cardiovascular Imaging is published 
on behalf of the American Heart 
Association, Inc., by Wolters Kluwer 
Health, Inc. This is an open access 
article under the terms of the Creative 
Commons Attribution License, 
which permits use, distribution, and 
reproduction in any medium, provided 
that the original work is properly cited.
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Atherosclerotic calcification is a complex patho-physiological process central to the development of advanced coronary artery plaques. Macroscopic 
coronary artery calcification can be quantified using com-
puted tomography, serving as an important surrogate 
measure of atherosclerotic plaque burden and providing 
powerful prognostic information beyond traditional risk 
factors.1–3 Furthermore, progression of coronary macrocal-
cification is associated with an increased risk of adverse 
cardiovascular events and all-cause mortality.4–6
The positron-emitting radiotracer 18F-sodium fluo-
ride (18F-fluoride), commonly used to detect patho-
logical metabolic activity in the skeletal system,7,8 can 
provide important insights into calcification activity 
within the cardiovascular system. 18F-fluoride binds to 
hydroxyapatite in proportion to the surface area of 
exposed crystal, such that it binds preferentially to areas 
of newly developing microcalcification where the sur-
face area is many fold higher than large macroscopic 
deposits.9 Microcalcification is a key healing response in 
atherosclerotic plaque,9 closely associated with necrot-
ic inflammation and high-risk disease, but ultimately 
leading to downstream coronary macrocalcification 
and plaque stabilization. 18F-fluoride positron emission 
tomography (PET)-CT, therefore, has the potential to 
act as a marker of disease activity in the coronary vascu-
lature by targeting a biologically important stage of the 
disease.10 Indeed, ex vivo studies have confirmed the 
exquisite sensitivity of 18F-fluoride for early microcalcific 
deposits and its association with high-risk plaque fea-
tures including macrophage infiltration and necrosis in 
atherosclerosis.11–13
Based on these principles, we hypothesized that 
coronary 18F-fluoride PET-CT should predict the future 
progression of coronary macrocalcification detected on 
CT. We, therefore, prospectively investigated the rela-
tionship between in vivo coronary 18F-fluoride uptake 
and the progression of coronary arterial calcification in 
patients with clinically stable coronary artery disease.
METHODS
Study Design
This study is a prespecified analysis of an investigator-initi-
ated double-blind randomized controlled trial conducted at 
a single centre in Edinburgh, UK.11 The study was approved 
by the local institutional review board, the Scottish Research 
Ethics Committee (REC reference: 14/SS/0089), Medicines 
and Healthcare products Regulatory Agency, and the United 
Kingdom Administration of Radiation Substances Advisory 
Committee. The study was performed in accordance with 
the Declaration of Helsinki and all patients provided written 
informed consent before any study procedures. The data that 
support the findings of this study are available from the cor-
responding author upon reasonable request.
Study Population
Patients with clinically stable multivessel coronary artery dis-
ease were recruited prospectively from the Edinburgh Heart 
Centre, United Kingdom, between March 2015 and March 
2017. Patients were included if aged over 40 years and with 
evidence of angiographically proven multivessel coronary 
artery disease, defined as at least 2 major epicardial vessels 
with any combination of either (1) >50% luminal stenosis or 
(2) previous revascularization (percutaneous coronary inter-
vention or coronary artery bypass graft surgery). Patients were 
excluded in the event of coronary revascularization within the 
preceding 3 months or acute coronary syndrome within the 
previous 12 months (Table I in the Data Supplement). Patients 
were randomized (1:1) to receive ticagrelor or placebo 
in addition to aspirin therapy, and the primary goal of the 
original study was to determine whether ticagrelor therapy, 
in addition to aspirin, reduces high-sensitivity troponin I con-
centration in participants with high-risk coronary plaque. The 
primary study results have been previously reported.14
Study Procedures
All participants underwent a baseline clinical assessment and 
combined 18F-fluoride PET-CT scanning with the acquisition 
of a contrast-enhanced CT coronary angiogram and noncon-
trast CT for calcium scoring. Before scanning, participants with 
a resting heart rate >65 beats/min were administered oral 
β-blockade (50–100 mg metoprolol) unless contraindicated. All 
participants were administered a target dose of 250 MBq intra-
venous 18F-fluoride and rested in a quiet environment. Sixty 
minutes following injection, PET acquisition was performed 
on a hybrid PET-CT scanner (64-multidetector Biograph mCT, 
CLINICAL PERSPECTIVE
Positron Emission Tomography using the radiotracer 
18F-fluoride can identify microcalcification and high-
risk plaque. In this study, the relationship between 
18F-fluoride activity and the progression of coro-
nary calcification was investigated in patients with 
clinically stable multivessel coronary artery disease. 
The results demonstrated more rapid progression 
of coronary calcification in patients with increased 
18F-fluoride activity at baseline. In individual lesions, 
baseline 18F-fluoride activity was an independent pre-
dictor of progression of calcification at one year. At 
the patient level, baseline calcium burden remained 
a more powerful predictor of calcium score at one 
year. These findings suggest that 18F-fluoride activity 
can provide an insight into disease activity in coro-
nary atherosclerosis. By providing early evidence of 
calcification activity, 18F-fluoride uptake may be use-
ful in clinical trials of novel therapies designed to 
modify disease progression. In the clinical setting, 
identifying patients with increased disease activity 
at risk of more rapid disease progression may enable 
targeting of intensified therapy.
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Siemens Medical Systems, Erlangen, Germany). Attenuation 
correction CT scans were performed before the acquisition of 
ECG-gated list-mode PET data using a single 30-minute bed 
position centred on the heart. Finally, an ECG-gated coronary 
CT angiogram was performed in mid-diastole during held expi-
ration following sublingual glyceryl trinitrate. Repeat coronary 
CT angiography and calcium scoring were performed using the 
same imaging protocol and on the same scanner at one year.
Image Analysis
Calcium Scoring
Noncontrast CT images for calcium scoring were reconstructed 
in the axial plane with 3 mm slice width and 1.5 mm increment. 
Coronary calcium was quantified on both a per-participant and 
per-segment level by an experienced observer using dedicated 
software (Vitrea Advanced, Toshiba Systems). Calcification 
was quantified as calcium score (AU), calcium volume (mm3) 
and calcium mass (mg). Calcium score was derived using the 
Agatston method.15 To calculate calcium mass, a calibration 
factor was derived using a phantom to calculate equivalent 
water diameter, adjusted for body mass index and lateral diam-
eter and applied at a specified X-ray tube voltage (Table II in the 
Data Supplement).16 Coronary stents were excluded from the 
per-patient analysis by only including calcium proximal or dis-
tal to the border of the stented segment. For the per-segment 
analysis, only segments without stenting were selected as rep-
resentative positive and negative segments.
Coronary CT Angiography Image Analysis
Visual assessment of CT-defined high-risk plaque character-
istics was performed by trained observers. The presence or 
absence of 5 plaque characteristics (positive remodeling, low 
attenuation plaque, the napkin ring sign, spotty calcification, 
and punctate calcification) was documented on a segmental 
basis using a 15-segment model.17 Positive remodeling was 
defined as a vessel diameter of 10% greater than a reference 
segment proximal to the plaque.18 Low attenuation plaque 
was defined as a focal area of plaque with an attenuation 
density of <30 Hounsfield units.19 Spotty calcification was 
defined as focal areas of arterial calcification with a maximum 
diameter <3 mm. The napkin ring sign was defined as a cen-
tral area of low attenuation plaque surrounded by a rim of 
high attenuation, as described previously.20
Coronary artery plaque quantification was performed 
on all nonstented segments with visible atherosclerotic 
plaque by a trained observer using semi-automated software 
(Autoplaque, Cedars Sinai Medical Center, Los Angeles). 
Plaque components including remodeling index, calcified 
plaque, noncalcified plaque and low attenuation plaque vol-
ume were quantified using scan-specific thresholds referenc-
ing blood pool attenuation from a circular region of interest 
created in the proximal ascending aorta. Manual adjustments 
were made as required. This technique has previously dem-
onstrated excellent intraobserver, inter-observer, and scan-
rescan reproducibility.21,22
PET Image Analysis
PET images were reconstructed in diastole (50%–75% of 
the R-R interval, 2 iterations, 21 subsets, 5 mm gaussian 
smoothing, Siemens Ultra-HD algorithm) and fused with 
contrast-enhanced CT coronary angiography. Images were 
co-registered on 3 anatomic planes and qualitative and semi-
quantitative analysis of coronary 18F-fluoride uptake was 
performed by experienced observers. Coronary 18F-fluoride 
PET-CT analysis and reproducibility have been reported pre-
viously.16 In brief, visual assessment for increased coronary 
18F-fluoride uptake was performed on both a per-participant 
and per-segment level and deemed positive if there was focal 
radiotracer accumulation which co-localized to an atheroscle-
rotic plaque on coronary CT angiography and followed the 
course of the coronary artery >5 mm in axial, sagittal, and 
orthogonal views. Where visual uptake was identified, semi-
quantitative analysis was performed by drawing 2-dimen-
sional regions of interest on the axial images and quantifying 
the maximum standardized uptake value for that lesion. In 
each participant, maximum standardized uptake value was 
also quantified in a proximal coronary atherosclerotic plaque 
without visual evidence of radiotracer localization as a refer-
ence. Background blood pool activity was quantified by mea-
suring activity in the right atrium within 2 cm radius regions of 
interest on three consecutive slices. Maximum tissue-to-back-
ground ratio (TBRmax) was calculated by dividing the plaque 
maximum standardized uptake value by the  mean average 
standardized uptake value in the right atrium. Coronary 
plaques were considered PET-positive in the presence of focal 
radiotracer uptake localized to a plaque with a TBRmax >1.25, 
as described previously.11 For the purpose of the per-segment 
analysis, participants were only included if there were both a 
PET-positive and PET-negative plaque which were not stented 
(Figure I in the Data Supplement). Participants in which the 
only PET-positive or PET-negative plaque was stented were 
excluded from per-segment analysis. Image analysis was 
performed using an OsiriX workstation (OsiriX version 3.5.1 
64-bit; OsiriX Imaging Software, Geneva, Switzerland).
Statistical Analysis
Categorical variables are reported as number (%) and con-
tinuous variables as mean±SD for parametric or median 
(interquartile range) for nonparametric data. Continuous 
unpaired variables were compared using Student t test or 
the Mann-Whitney U test where appropriate and paired 
variables compared using Student t test or the Wilcoxon 
matched-pairs signed-ranks test, dependent on normal-
ity. Categorical variables were compared using χ2 tests. 
Logarithmic transformation (Ln[x+1]) was used to achieve 
normality of continuous variables. Two-tailed Pearson corre-
lation analysis was performed to investigate the relationship 
between continuous variables where normally distributed. 
Nonparametric continuous variables were compared using 
Spearman rank correlation. To investigate the relationship 
between 18F-fluoride activity and progression of coronary 
calcification at the patient level, linear regression was used 
with log transformation of the dependent variable. To inves-
tigate at the per-segment level, a linear mixed model was 
used with the participant as a random effect to adjust for 
repeated measurements within individuals. Using calcium 
mass at 12 months as the dependent variable, ANOVA was 
then used to compare 2 mixed models; model one using cal-
cium mass at baseline, and model 2 using baseline calcium 
and segmental TBR as independent variables. Statistical 
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analysis was undertaken using IBM SPSS Statistics 23 and 
R version 3.5.0 (R Foundation for Statistical Computing, 
Vienna, Austria). Statistical significance was considered as 
a 2-sided P<0.05.
RESULTS
A total of 185 participants underwent combined PET-
CT angiography and CT calcium scoring at baseline 
and follow-up (mean age 65±8, 80% male; Figure 
II in the Data Supplement). For the purposes of this 
analysis, we excluded participants who underwent 
coronary revascularization during the course of the trial 
with implantation of a coronary stent within a previ-
ously unstented coronary segment (n=2). Coronary 
revascularization decisions were made by the attend-
ing clinician independent of the research study team 
or knowledge of the PET-CT scan findings. Of the par-
ticipants who underwent percutaneous coronary inter-
vention, both had evidence of increased 18F-fluoride 
activity. One participant underwent stenting to the left 
anterior descending artery and left circumflex artery, 
and the other underwent stenting to the left anterior 
descending artery. All 3 lesions showed obstructive ste-
nosis on the baseline scan (70%–99% stenosis) and 2 
of 3 had high-risk plaque features (positive remodel-
ing and spotty calcification). In the remaining eligible 
participants (n=183), there was a high prevalence of 
cardiovascular risk factors, of which 69% (n=126) had 
a history of acute coronary syndrome, 81% (n=148) of 
participants had previous percutaneous coronary inter-
vention, and the majority 96% (n=175) were on statin 
therapy (Table 1).
Of the 183 participants included in this analy-
sis, 63% (n=116) patients had evidence of increased 
18F-fluoride uptake in at least one vessel (PET-positive). 
The PET-positive cohort was predominantly male (89%, 
n=103% versus 64%, n=43; P<0.001), with a higher 
prevalence of prior coronary artery bypass graft surgery 
(28%, n=33% versus 6%, n=4; P<0.001).
Table 1. Baseline Characteristics
 
All participants, 
n=183
PET-positive 
participants, n=116
PET-negative 
participants, n=67 P value
Male gender 146 (80) 103 (89) 43 (64) <0.001†
Age, y 66 (59–71) 67 (61–73) 65 (57–70) 0.02†
BMI, kg/m2 29.5 29.3 29.9 0.35
Medical history
  Current smoker 24 (13) 12 (10) 12 (18) 0.14
  History of acute coronary syndrome 126 (69) 80 (69) 46 (69) 0.97
  Percutaneous coronary intervention 148 (81) 93 (80) 56 (84) 0.48
  Coronary artery bypass grafting 37 (20) 33 (28) 4 (6) <0.001†
  Hypertension 101 (55) 65 (56) 36 (54) 0.76
  Chronic kidney disease stage 3* 9 (5) 6 (5) 3 (4) 0.83
  Hypercholesterolemia 177 (97) 112 (97) 65 (97) 1.0
  Diabetes 32 (17) 22 (19) 10 (15) 0.58
  Prior stroke/transient ischemic attack 4 (2) 3 (3) 1 (1) 1.0
Medications
  Aspirin 183 (100) 116 (100) 67 (100)  
  Statin 175 (96) 110 (95) 65 (97) 0.71
  Beta-blocker 124 (68) 78 (67) 46 (69) 0.84
  Angiotensin-converting enzyme 
inhibitor/angiotensin II receptor blocker
138 (75) 86 (74) 52 (78) 0.60
Biochemistry
  Hemoglobin, g/dL 14.0±1.2 14.0±1.2 14.0±1.3 0.87
  Creatinine, mg/dL 0.9±0.15 0.9±0.15 0.9±0.15 0.89
  Total cholesterol, mmol/L 4.3±1.0 4.3±1.0 4.2±0.8 0.33
  High-density lipoprotein, mmol/L 1.2±0.3 1.2±0.3 1.1±0.3 0.46
  Low-density lipoprotein, mmol/L 2.2±0.8 2.3±0.8 2.1±0.7 0.14
  Triglycerides, mmol/L 1.7±1.0 1.7±1.2 1.7±0.8 0.79
BMI indicates body mass index; and PET, positron emission tomography.
*Estimated glomerular filtration rate 30–60 mL/min per 1.73 m2.
†Indicates statistical significance.
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Baseline 18F-Fluoride Activity and Per-
Participant Calcium Burden
Participants with increased coronary 18F-fluoride uptake 
had higher baseline calcium scores (524 [242–1091] 
versus 136 [55–361] AU; P<0.001), higher calcium 
mass (99 [46–212] versus 24 [11–69] mg; P<0.0001), 
and higher calcium volume (491 [247–984] versus 131 
[64–343] mm3; P<0.0001) compared with those with-
out increased 18F-fluoride uptake (Table 2). The propor-
tion of PET-positive participants rose with increasing 
baseline calcium score (Figure  1). Thirty-eight partici-
pants had a total calcium score >1000 Agatston units 
at baseline and, of these, 35 (92%) had evidence of 
increased 18F-fluoride uptake in at least one vessel.
18F-Fluoride Uptake and Plaque 
Characteristics
Sixty (52%) of the PET-positive participants and 37 
(55%) of the PET-negative participants had at least 
one high-risk plaque feature on CT coronary angiogra-
phy. There was no difference in the median number of 
high-risk plaque features per-patient in PET-positive (1.0 
[0.0–2.3]) compared with PET-negative (1.0 [0.0–3.0]) 
participants (Table III in the Data Supplement). Nine 
participants were excluded from quantitative plaque 
analysis due to suboptimal image quality. On quantita-
tive plaque analysis in the remaining 174 participants, 
total plaque volume, noncalcified plaque volume, and 
calcified plaque volume were higher in PET-positive par-
ticipants at baseline and at 1-year follow-up (Table 3).
18F-Fluoride Uptake and Progression of 
Calcification on a Per-Patient Level
The median increase in calcium score, calcium mass, 
and calcium volume were higher in PET-positive com-
pared with PET-negative participants (P<0.001 for all; 
Table 2). Change in total calcified plaque volume on CT 
coronary angiography was also higher in PET-positive 
participants. There was no difference in change in non-
calcified plaque, low-density plaque, or total plaque 
volume (Table  3). Per-patient TBRmax correlated with 
change in calcium score (Spearman ρ=0.37), calcium 
mass (ρ=0.46), and calcium volume (ρ=0.38; P<0.001 
for all; Table 4). There was a weak positive correlation 
between baseline TBRmax and change in total calcified 
plaque volume (Spearman’s ρ, 0.165; P=0.029; Table 4).
After adjusting for age, sex, and baseline calcium 
score, baseline 18F-fluoride activity was not an inde-
pendent predictor of calcium score at 12 months when 
investigated at the patient level (P=0.50).
Per-Segment 18F-Fluoride Activity and 
Progression of Calcification
Calcification in individual coronary segments with 
evidence of 18F-fluoride uptake was compared with a 
proximal reference segment with atherosclerotic plaque 
but without increased 18F-fluoride uptake within the 
same individual (Figure  2). Six participants, in whom 
the only PET-positive lesion or only PET-negative lesion 
was stented, were excluded from analysis. Among the 
remaining PET-positive participants (n=110), lesions 
with 18F-fluoride uptake had a higher calcium score, 
calcium mass, and volume at baseline than PET-nega-
tive reference lesions in the same individuals (P<0.001 
for all; Table  5). There was no difference in baseline 
average calcium density or change in average calcium 
density between PET-positive and PET-negative lesions 
(Supplemental Table IV in the Data Supplement).
In PET-positive segments, there was an increase in 
calcium score (from 95 [30–209] to 148 [61–289] AU), 
calcium mass (from 19 [6–40] to 28 [11–55] mg), and 
Table 2. Progression of Calcification in Participants With Evidence of Increased 18F-Fluoride Uptake Compared With Those Without Uptake
 
All participants 
(n=183)
PET-positive 
participants (n=116)
PET-negative 
participants (N=67) P value
Baseline
  Total Agatston score, AU 378 (107–823) 524 (242–1091) 136 (55–361) P<0.001*
  Calcium volume, mm3 352 (131–771) 491 (247–984) 131 (64–343) P<0.001*
  Calcium mass, mg 70 (23–153) 99 (46–212) 24 (11–69) P<0.001*
Follow-up
  Total Agatston score, AU 476 (173–1045) 660 (292–1216) 165 (61–461) P<0.001*
  Calcium volume, mm3 417 (167–887) 611 (313–1041) 149 (68–407) P<0.001*
  Calcium mass, mg 89 (32–195) 129 (58–241) 32 (11–81) P<0.001*
Progression
  Change in calcium score, AU 70 (22–143) 97 (39–166) 35 (7–93) P<0.001*
  Change in calcium volume, mm3 60 (16–121) 82 (29–149) 33 (3–82) P<0.001*
  Change in calcium mass, mm3 14 (4–35) 22 (7–42) 6 (1–20) P<0.001*
PET-positive and PET-negative denote the presence or absence of 18F-fluoride uptake. PET indicates positron emission tomography.
*Indicates statistical significance.
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calcium volume (from 106 [37–185] to 129 [62–226] 
mm3; P<0.001 for all). In PET-negative reference seg-
ments, there was no change in calcium score (from 46 
[16–113] to 49 [20–115] AU; P=0.329) and calcium 
volume (from 46–44 mm3, P=0.666), although there 
was a small increase in calcium mass (from 9.1–9.2 mg; 
P=0.017; Figure  3). Similarly, changes in calcification 
were greater in PET-positive plaques compared with 
PET-negative plaques for the calcium score (39 [20–70] 
versus 2 [−7 to 11] AU), calcium mass (7 [4–14] versus 
0.6 [−0.8 to 2.1] mg) and calcium volume (30 [14–53] 
versus 1 [−8 to 8] mm3; P<0.001 for all). When seg-
mental calcium mass and calcium score were measured 
as a ratio of follow-up to baseline, the calcium mass 
and calcium score ratio were each higher in PET-positive 
segments (Figure 4).
When the relationship between 18F-fluoride activity 
and progression of calcification was investigated at the 
segmental level, baseline TBRmax was an independent 
predictor of 12-month calcium mass when adjusting 
for baseline calcium mass (beta 0.67 SE 0.06), Agatston 
score (beta 0.60 SE 0.09) or volume (beta 0.52 SE 0.07), 
Table 3. Quantitative Plaque Features in PET-Positive and PET-Negative Participants
 
All participants 
(n=174)
PET-positive 
participants (n=110)
PET-negative 
participants (n=64) P value
Baseline
  Total plaque volume, mm3 1361 (1033 to 1994) 1551 (1122 to 2080) 1142 (905 to 1488) <0.0001*
  Noncalcified plaque volume, mm3 1274 (953 to 1692) 1459 (1063 to 1819) 1118 (873 to 1443) 0.001*
  Calcified plaque volume, mm3 89 (34 to 224) 154 (62 to 285) 37 (7 to 78) <0.0001*
  Low-density noncalcified plaque volume, mm3 87 (43 to 168) 91 (54 to 154) 78 (35 to 169) 0.485
  Remodeling index 1.5 (1.4 to 1.7) 1.5 (1.4 to 1.8) 1.4 (1.3 to 1.6) 0.02*
Follow-up
  Total plaque volume, mm3 1493 (1097 to 2062) 1639 (1282 to 2298) 1270 (969 to 1600) <0.0001*
  Noncalcified plaque volume, mm3 1366 (1032 to 1831) 1492 (1099 to 1977) 1228 (936 to 1561) 0.005*
  Calcified plaque volume, mm3 109 (38 to 223) 161 (79 to 300) 43 (13 to 79) <0.0001*
  Low-density noncalcified plaque volume, mm3 91 (48 to 157) 84 (49 to 153) 104 (41 to 161) 0.829
  Remodeling index 1.5 (1.3 to 1.7) 1.5 (1.3 to 1.7) 1.4 (1.3 to 1.6) 0.438
Progression
  Change in total plaque volume, mm3 93 (−92 to 270) 90 (−104 to 296) 93 (−82 to 255) 0.776
  Change in noncalcified plaque volume, mm3 87 (−92 to 230) 75 (−113 to 233) 108 (−72 to 227) 0.708
  Change in calcified plaque volume, mm3 4 (−13 to 37) 14 (−12 to 47) 1 (−15 to 17) 0.02*
  Change in low-density noncalcified plaque volume, mm3 2 (−20 to 28) 1 (−23 to 26) 3 (−16 to 32) 0.558
PET indicates positron emission tomography.
*Indicates statistical significance.
Figure 1. The proportion of 18F-fluoride posi-
tive and negative participants with increas-
ing baseline total calcium score.
Increased overall disease burden is associated 
with an increased frequency of 18F-fluoride 
activity.
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and the repeated within individual measurements 
(P<0.001 for all).
DISCUSSION
In this prespecified sub-study of a randomized con-
trolled trial, we have demonstrated that increased 
18F-fluoride uptake is associated with more rapid pro-
gression of coronary atherosclerotic calcification. This 
finding was consistent across a range of measures of 
calcification and whether this was considered on a 
per-patient or per-segment basis. However, when con-
sidering total calcification burden at the patient level, 
baseline calcium score remained a powerful predictor 
of calcification progression. These findings nonetheless 
support 18F-fluoride PET as a marker of increased dis-
ease activity and active mineralization within coronary 
atherosclerotic plaques.
Calcification plays a complex role in the develop-
ment and progression of atherosclerosis. Hydroxyapa-
tite deposition is heralded by intense inflammation, 
cell death and necrosis which precipitate the forma-
tion of calcifying matrix vesicles and lead to the earliest 
microscopic deposits of calcium which are not visible 
on conventional anatomic imaging modalities.10,12,23 As 
well as reflecting the proinflammatory environment, 
microcalcification may also be directly implicated in 
plaque rupture as a consequence of destabilization 
of the plaque’s fibrous cap.24 As microcalcific deposits 
coalesce to form larger macroscopic structures, plaque 
stability improves—a feature reflected by the obser-
vation that heavily calcified plaques are less prone to 
rupture or precipitate acute coronary events.25,26 Thus, 
while advanced macrocalcification may be considered 
a marker of plaque stability and inert disease, the ear-
lier stages of calcium deposition are associated with 
increased inflammation and plaque vulnerability.23,27
The precise natural history of calcification activ-
ity remains poorly understood. Indeed, the process of 
calcification does not progress in a linear manner and, 
while the earliest microcalcific deposits are associated 
with intense inflammation,10 it is likely that active cal-
cification may accelerate during the process of plaque 
healing. This observation is concordant with prior ran-
domized trials that have observed a procalcific effect of 
statins due to phenotypic transformation of low atten-
uation material to calcified plaque.24 While computed 
tomography can provide quantitative measures of total 
plaque burden, it does not provide insight into the 
underlying biological disease process or disease activity, 
hence the rationale for using targeted radiotracers.
18F-fluoride preferentially binds developing microcal-
cification,24 with uptake, therefore, potentially reflecting 
the earlier and more unstable stages of atherosclerotic 
mineralization. Here, we have confirmed that increased 
18F-fluoride uptake provides an assessment of calcifica-
tion activity within the coronary arteries, with uptake 
predicting progression in macroscopic calcium mea-
sured in individual plaques on CT (Figure 1), similar to 
previous results in the aortic valve and mitral valve annu-
lus.28,29 Indeed, while calcium scores remained static in 
lesions without uptake, there was progression of calci-
fication in plaques with increased 18F-fluoride uptake, 
with an ≈50% increase in median calcium score and 
calcium mass in as little as 12 months. Furthermore, 
the median change in calcium score in individual lesions 
with 18F-fluoride uptake was almost 20× greater than 
the change in calcium score in those without uptake. In 
individual coronary lesions, this finding remained even 
following adjustment for baseline calcium mass.
While the temporal nature of 18F-fluoride activity 
remains unknown, it is possible that 18F-fluoride uptake 
may increase as the atheromatous plaque begins to 
stabilize. Previous reports have highlighted that, while 
coronary 18F-fluoride uptake can be localized to culprit 
plaques in the majority of patients following acute myo-
cardial infarction, quantitative PET activity, as measured 
by tissue-to-background ratio, is higher in patients with 
stable coronary artery disease compared with immedi-
ately following acute myocardial infarction.11 In a recent 
post hoc analysis of nearly 300 patients with estab-
lished coronary artery disease, increased 18F-fluoride 
activity was an independent predictor of fatal and non-
fatal myocardial infarction. Quantification of coronary 
microcalcification activity, a novel marker of 18F-fluoride 
Table 4. Correlation Between Baseline TBRmax and Progression of 
Calcification
 
Number of 
participants
TBRmax 
correlation 
coefficient 
(Spearman’s ρ) P value
Calcium burden on noncontrast CT
  Change in total 
calcium burden, AU/y
183 0.371 <0.001*
  Change in total 
calcium volume, 
mm3/y
183 0.379 <0.001*
  Change in total 
calcium mass, mg/y
183 0.456 <0.001*
Quantitative plaque characteristics on CT coronary angiography
  Change in total plaque 
volume, mm3/y
174 0.054 0.476
  Change in noncalcified 
plaque volume, mm3/y
174 −0.001 0.990
  Change in low 
attenuation plaque 
volume, mm3/y
174 −0.011 0.884
  Change in calcified 
plaque volume, mm3/y
174 0.165 0.029*
CT indicates compured tomography; and TBRmax, maximum tissue-to-
background ratio.
*Indicates statistical significance.
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uptake, demonstrated powerful prediction of future 
adverse events leading to a 7-fold increased risk of fatal 
or nonfatal myocardial infarction in participants with 
elevated coronary microcalcification activity.30
In the present study, we have for the first time linked 
coronary 18F-fluoride activity to progression in coronary 
atherosclerotic calcification. The main hypothesis for this 
study was to investigate the relationship between 18F-flu-
Table 5. Progression of Calcification at a Segmental Level in Coronary Arterial Segments With and Without Increased 
18F-Fluoride Uptake in PET Positive Participants
 
PET-positive 
participants 
(n=110)
PET-positive 
individual plaques 
(n=110)
PET-negative 
reference plaques 
(N=110) P value
Baseline
Total Agatston score, AU 548 (260 to 1130) 95 (30 to 209) 46 (16 to 113) <0.001*
Calcium volume, mm3 519 (276 to 1014) 106 (37 to 185) 47 (21 to 95) <0.001*
Calcium mass, mg 101 (51 to 222) 19 (6 to 40) 9 (4 to 21) <0.001*
Follow-up
Total Agatston score, AU 679 (346 to 1257) 148 (61 to 289) 49 (20 to 115) <0.001*
Calcium volume, mm3 651 (330 to 1094) 129 (62 to 226) 44 (21 to 103) <0.001*
Calcium mass, mg 131 (62 to 242) 28 (11 to 55) 9 (4 to 23) <0.001*
Progression
Change in calcium score, AU 104 (45 to 170) 39 (20 to 70) 2 (−7 to 11) <0.001*
Change in calcium volume, mm3 86 (35 to 154) 30 (14 to 53) 1 (−8 to 8) <0.001*
Change in calcium mass, mg 23 (10 to 44) 7 (4 to 14) 0.62 (−0.8 to 2.1) <0.001*
PET-positive and PET-negative denote the presence or absence of 18F-fluoride uptake. PET indicates positron emission tomography.
*Indicates statistical significance. 
Figure 2. 18F-fluoride activity predicts progression of coronary arterial calcification.
In an 18F-fluoride positron emission tomography (PET) positive lesion (A–E), contrast-enhanced computed tomography (CT) coronary angiography (A) and fused 
PET-CT (B) demonstrate 18F-fluoride uptake in the left main stem (LMS) at baseline overlying a mixed plaque shown on coronal view (A) and cross-section (C). 
Repeat CT coronary angiography at one year demonstrates progression of calcification in this segment with a higher calcium score (D) and dense calcium 
visible on cross-section (E). Calcium score 75 AU at baseline, maximum tissue-to-background ratio (TBRmax) 1.7, calcium score 110 AU at one year. In the same 
patient, a calcified plaque in a proximal obtuse marginal branch without evidence of increased 18F-fluoride activity is shown on coronal (F and G) and cross-
section views (H). This plaque does not demonstrate progression in calcium score at one year (I and J). Calcium score 186 AU at baseline, TBRmax 1.0, calcium 
score 172 AU at one year.
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oride activity and calcification progression. However, we 
also investigated the relationship between PET activity and 
other morphological features of atherosclerosis, including 
low attenuation plaque, noncalcified plaque and total 
plaque volume. We have demonstrated that total plaque 
volume and noncalcified plaque volume are higher in 
patients with increased 18F-fluoride activity. The presence 
of increased 18F-fluoride activity was also associated with 
a greater change in total calcified plaque volume.
The study highlights the high frequency of increased 
18F-fluoride activity in patients with established multives-
sel coronary artery disease, with two-thirds of patients 
having evidence of increased activity in at least one ves-
sel. The prevalence of increased 18F-fluoride uptake is 
similar to previous reports in clinically stable patients.11,31 
Previous studies have reported that over one third of 
patients with calcium scores greater than 1000 do not 
have evidence of increased 18F-fluoride activity.31 In this 
study, we have shown that the majority of patients (92%) 
with calcium scores greater than 1000 had evidence of 
increased 18F-fluoride uptake in at least one vessel, sug-
gesting ongoing calcification activity. Indeed, an increas-
ing disease burden was associated with an increase in 
the proportion of patients with evidence of increased PET 
activity in at least one vessel. This may reflect the underly-
ing study population whom were largely high risk, with 
the majority (70%) having prior acute coronary syndrome 
and over 80% having previous coronary revascularization.
We recognize that there are some limitations to our 
study. PET-CT imaging was performed in a single cen-
ter with experience in coronary PET-CT, and we need to 
explore the generalizability of our findings across mul-
tiple centers with different scanners. The high preva-
lence of previous percutaneous coronary intervention 
and stenting precluded calcium scoring assessment 
from at least one arterial segment in many patients. We 
mitigated for this by excluding those participants who 
underwent revascularization in a previously untreated 
arterial segment before the follow-up scan, ensuring the 
calcium burden on the follow-up scan was not underes-
timated. Although scan-rescan reproducibility of CT cal-
cium mass and volume within individual plaques has not 
been reported, repeatability and variability of CT calcium 
scoring protocols has been demonstrated to be <20%.32 
Figure 3. The relationship between baseline 18F-fluoride activity and coronary calcification at one year.
A–C, Display the change in calcium score (A), mass (B), and volume (C) in 18F-fluoride positive vs negative lesions over 12 months. Median and interquartile range 
displayed.
Figure 4. Ratio of calcification at follow-up to baseline.
Ratio of follow-up total calcium mass (A) and Agatston score (B) to baseline in individual positron emission tomography (PET)-positive and PET-negative segments 
in participants with at least one PET-positive lesion.
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Furthermore, our scans were all performed on a single 
imaging system with the same scanning protocol and 
reconstruction protocol, thereby minimizing interscan 
variability. Lastly, our population represents a high-risk 
patient group with advanced disease, and the major-
ity having had a previous acute coronary event. Hence, 
these results may not be applicable to all patients with 
known or suspected coronary disease and future stud-
ies in different risk groups would be welcomed. While 
recent data have highlighted the predictive value of 
18F-fluoride activity in cardiovascular risk stratification, 
ultimately, prospective studies investigating the relation-
ship between coronary 18F-fluoride uptake and cardio-
vascular events will determine the prognostic utility of 
this novel imaging method and observational studies in 
this field are ongoing (PREFFIR, URL: https://www.clini-
caltrials.gov; Unique identifier: NCT02278211).
In conclusion, increased coronary 18F-fluoride uptake 
is associated with more rapid progression of coronary 
calcification at one year in patients with clinically sta-
ble multivessel coronary artery disease. In individual 
diseased segments, this association is independent 
of baseline calcium score, but at the patient level this 
finding is not independent of baseline calcium burden. 
18F-fluoride uptake provides new insights into disease 
activity and progression of coronary atherosclerosis.
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